After a prolonged period where growth remained uneven in the wake of global disruptions, a pivotal metric for biopharma research…
Read More
Pharmaceutical R&D Returns Soar to 7% Driven by GLP-1 Blockbusters, Raising Sustainability Questions for the Industry
After a period characterized by uneven growth and strategic recalibrations in the wake of global health challenges, a key metric…
Read More
Deloitte report showed pharma returns rising to 7%. GLP-1s did most of the work.
After a period of post-pandemic uncertainty and uneven growth, a closely monitored metric of biopharmaceutical research and development (R&D) productivity…
Read More
Pharma R&D Returns Soar to 7% Driven Almost Exclusively by GLP-1 Therapies, Deloitte Report Reveals
The pharmaceutical industry, after a period characterized by uneven growth and post-pandemic recalibration, is witnessing a significant upturn in R&D…
Read More
Deloitte report showed pharma returns rising to 7%. GLP-1s did most of the work.
The pharmaceutical industry, emerging from a period characterized by uneven growth and significant challenges in research and development (R&D) productivity,…
Read More
Deloitte Report Reveals Pharma R&D Returns Surge to 7% Driven Primarily by GLP-1 Blockbusters, Raising Sustainability Concerns
A new report from Deloitte, titled "Navigating the GLP-1 boom," indicates a significant resurgence in biopharma R&D productivity, with the…
Read MoreYOU MAY HAVE MISSED
